L. Jeantin, MD, T. Lenfant, MD, P. Charles, MD, Department of Internal Medicine, Institut Mutualiste Montsouris, Paris.
P. Bataille, MD, Department of Nephrology, CH Boulogne-sur-Mer, Boulogne-sur-Mer.
J Rheumatol. 2022 Dec;49(12):1349-1355. doi: 10.3899/jrheum.211379. Epub 2022 Jul 15.
While myocardial impairment is a predictor of poor prognosis in antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV), little is known about valvular involvement. This study aims at describing the clinical presentation, management, and outcome of endocarditis associated with AAV.
We conducted a multicenter retrospective study in centers affiliated with the French Vasculitis Study Group. We included patients with granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), or eosinophilic GPA with endocardial impairment. A systematic review was then performed through PubMed, Embase, and Cochrane Library from inception up to September 2020.
The retrospective cohort included 9 patients (82%) with GPA, 1 (9%) with MPA, and 1 (9%) with unclassified AAV. Clinical presentation included acute valvular insufficiency (n = 7, 64%), cardiac failure (n = 3, 27%), dyspnea (n = 3, 27%), and no symptoms (n = 2, 18%). The aortic valve was the most frequently affected (n = 8/10, 80%), and vegetations were noted in 4 of 10 patients (40%). Six patients (55%) underwent surgical valvular replacement. No death from endocarditis was reported. The systematic review retrieved 42 patients from 40 references: 30 (71%) had GPA, 21 (50%) presented with vegetations, the aortic valve (n = 26, 62%) was the most frequently involved. Valvular replacement was required in 20 cases (48%) and 5 patients (13%) died from the endocarditic impairment.
Endocarditis is a rare and potentially life-threatening manifestation of AAV. Acute valvular insufficiency may lead to urgent surgery. Implementing transthoracic echocardiography in standard assessment at baseline and follow-up of AAV might reduce the delay to diagnosis and allow earlier immunosuppressive treatment before surgery is needed.
虽然心肌损伤是抗中性粒细胞胞质抗体(ANCA)相关性血管炎(AAV)预后不良的预测因素,但对于瓣膜受累知之甚少。本研究旨在描述与 AAV 相关的心内膜炎的临床表现、治疗和结局。
我们在隶属于法国血管炎研究组的中心进行了一项多中心回顾性研究。我们纳入了肉芽肿性多血管炎(GPA)、显微镜下多血管炎(MPA)或嗜酸性粒细胞性 GPA 伴心内膜损伤的患者。然后通过 PubMed、Embase 和 Cochrane Library 进行了系统评价,检索时间截至 2020 年 9 月。
回顾性队列包括 9 例(82%)GPA、1 例(9%)MPA 和 1 例(9%)未分类 AAV 患者。临床表现包括急性瓣膜功能不全(n = 7,64%)、心力衰竭(n = 3,27%)、呼吸困难(n = 3,27%)和无症状(n = 2,18%)。主动脉瓣最常受累(n = 8/10,80%),10 例患者中有 4 例(40%)可见赘生物。6 例(55%)患者接受了手术瓣膜置换。没有因心内膜炎而死亡的病例。系统评价从 40 篇参考文献中检索到 42 例患者:30 例(71%)为 GPA,21 例(50%)存在赘生物,主动脉瓣(n = 26,62%)最常受累。20 例(48%)需要瓣膜置换,5 例(13%)死于心内膜炎。
心内膜炎是 AAV 的一种罕见且潜在危及生命的表现。急性瓣膜功能不全可能导致紧急手术。在 AAV 的基线和随访标准评估中实施经胸超声心动图可能会减少诊断延迟,并允许在需要手术之前更早地进行免疫抑制治疗。